By DAVID RANII
Posted on Wednesday, Jan. 25, 2012
After a tumultuous year that featured the dismissal of its CEO, drug-development company Oxygen Biotherapeutics is starting 2012 in its best financial shape in years.
The small, publicly traded Morrisville company turned a financial corner at the end of last year when it sold $7.5 million in preferred stock and warrants to institutional investors. The company received $3.5 million in December, with the second installment expected midyear.
In the past, Oxygen Bio has raised money that would carry it forward for about six months, but this was a richer deal. More...
-
Oxygen Biotherapeutics to Begin Clinical Study to Determine Efficacy of Dermacyte(R) in Relieving Histamine Induced Pruritus
MORRISVILLE, N.C., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) announced today that enrollment for the company's first dermatological study will begin later this month at St. John's Medical College Hospital in Bangalore, India. The company received formal approval from the hospital's Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne. More...
-
Oxygen Biotherapeutics Names Two New Board Members With Pharmaceutical Industry, Product and Business Development Emphasis
MORRISVILLE, N.C., Dec. 19, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has named Chris A. Rallis, Executive-in-Residence at Pappas Ventures, and Anthony A. DiTonno, President and Chief Executive Officer of Neurogesx Inc., to serve as members of the company's Board of Directors, effective December 15, 2011. The addition of these two directors increases the Board to five members.More...
-
Oxygen Biotherapeutics Announces Registered Financing for up to $7.5 Million in Gross Proceeds
MORRISVILLE, N.C., Dec 9, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT) today announced that it has entered into definitive agreements with institutional investors for up to $7.5 million in gross proceeds. Under the terms of the agreements, Oxygen will issue registered shares of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock"), and registered warrants ("Warrants") to purchase shares of the Company's common stock, par value $0.0001 per share. The transaction provides for 50% Warrant coverage on the Preferred Stock, based on the number of shares of common stock initially issuable under the Preferred Stock. More...
-
Oxygen Biotherapeutics to Present at 23rd Annual Piper Jaffray Healthcare Conference
MORRISVILLE, N.C., Nov. 22, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT) today announced that Chief Financial Officer and Interim CEO Michael Jebsen will present at the upcoming 23rd Annual Piper Jaffray Healthcare Conference on November 30, 2011 at 1:30 pm ET, at The New York Palace Hotel in New York City. More...
-
Oxygen Biotherapeutics to Voluntarily Withdraw Secondary Listing From SIX Swiss Stock Exchange
MORRISVILLE, N.C., Oct 27, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT) today announced that the SIX Swiss Stock Exchange has approved the application filed by the company on September 30, 2011, to remove the company's shares from trading on the SIX exchange. This application was filed after the Company's Board of Directors determined that the cost of maintaining the SIX listing was not justified in light of the low trading volume of the Company's shares over the past 12 months. The last day of trading for the company's common stock on the SIX will be January 30, 2012. More...
-
Oxygen Biotherapeutics Names Dr. Ronald Blanck Chairman of the Board
MORRISVILLE, N.C., Sep 30, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that Ronald R. Blanck, DO, was appointed Chairman of the Board of Directors of the company.
The company also reported that in light of the shareholder vote received today at the General Annual Meeting of Shareholders Rene A. Eckert and J. Melville Engle resigned as directors of the company. Neither of the resignations was the result of any disagreement with the company or the Oxygen Board of Directors. More...
-
Oxygen Biotherapeutics Reports First Quarter FY2012 Financial Results and Announces Conference Call and Webcast for Shareholders
MORRISVILLE, N.C., Sep 19, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) 2012 first quarter ended July 31, 2011. The company also announced that the company will host a conference call regarding these results on Tuesday, September 20, 2011 at 10:30 AM EDT. (see conference call access details below). More...
-
Photo Release -- Beat the Summertime Skin Blues With Dermacyte® Summer Rescue Bundle to Soothe Dry Skin and Bring Back a Youthful Glow
More and More U.S. Dermatologists are Recommending DERMACYTE to Their Clients
MORRISVILLE, N.C., Aug 1, 2011 (GlobeNewswire via COMTEX) --
Let's face it: summer is fun, but it can be tough on your skin. Most of us spend more hours outdoors in summer than during any other season doing activities that can take a major toll on our skin, particularly our faces. More...
-
Oxygen Biotherapeutics and Aurum Biosciences Sign Letter of Intent to Explore the Use of Oxycyte(R) PFC for Imaging and Therapeutic Intervention of Acute Ischemic Stroke
MORRISVILLE, N.C., Jul 25, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) and privately held Aurum Biosciences, Ltd. of Glasgow, Scotland, today announced they signed a Letter of Intent (LOI) to conduct preclinical research for imaging and therapeutic intervention of acute ischemic stroke. The research will be conducted by Aurum using Oxygen's proprietary Oxycyte(R) PFC (perfluorocarbon) emulsion in combination with Aurum's proprietary Glasgow Oxygen Level Dependent (GOLD) Magnetic Resonance Imaging techniques. More...
-
Global Interest in the Potential Medical Benefits of Novel Perfluorocarbon At All Time High
-
Oxygen Biotherapeutics Announces It Has Material Transfer Agreements in Place With Universities, Research Institutions Worldwide and the US Military
MORRISVILLE, N.C., Jul 20, 2011 (GlobeNewswire via COMTEX) --
University and educational institution researchers from the United Kingdom, Switzerland and the United States all have one thing in common: an interest in exploring the properties of a novel perfluorocarbon that was developed by an emerging development-stage biomedical company named Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT). More...
-
Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2011
MORRISVILLE, N.C., Jul 14, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) ended April 30, 2011. More...
-
Oxygen Biotherapeutics Announces Closing of Its Previously Announced Private Placement of Unregistered Convertible Notes and Warrants
MORRISVILLE, N.C., Jul 1, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that it closed its previously announced private placement of unregistered convertible notes (the "Notes") and unregistered warrants ("Warrants"). The final amount of transaction was $4.9 million, an increase from the previously reported $4.6 million, as a result of an additional $0.3 million in Notes and Warrants that were offered and sold to an additional institutional investor. The transaction resulted in gross proceeds of $4.9 million to Oxygen, excluding any proceeds from exercise of the Warrants, and aggregate placement agent fees of approximately $297,000. More...
-
Oxygen Biotherapeutics Announces $4.6 Million Private Placement of Unregistered Convertible Note and Warrants
MORRISVILLE, N.C., Jun 22, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that it has entered into an agreement for the issuance and sale of an unregistered convertible note with a principal amount of $4.6 million (the "Note") and unregistered warrants ("Warrants") in a private placement to an institutional investor. Upon consummation, the transaction is expected to result in gross proceeds of $4.6 million to Oxygen, excluding any proceeds from exercise of the Warrants, and aggregate placement agent fees of approximately $276,000. More...
-
Oxygen Biotherapeutics Receives Approval to Expand Phase IIb Trials With Oxycyte® PFC for Traumatic Brain Injury Into India
MORRISVILLE, N.C., Jun 7, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has received approval by the Drug Controller General of India to conduct its traumatic brain injury Phase IIb clinical trials known as STOP-TBI. Oxygen Biotherapeutics believes adding clinical investigators in India to its existing clinical sites in Switzerland and Israel will enable the Company to conclude the study faster and more economically. The next cohort is expected to begin in the second half of fiscal year 2012. More...
Oxygen Biotherapeutics' Chairman and CEO Chris Stern Announces Retirement of President and COO Richard Kiral Dr. Richard Kiral Will Remain a Director and Consultant to the Company
MORRISVILLE, N.C., Mar 31, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced the Board of Directors accepted the resignation of President and Chief Operating Officer Richard Kiral, Ph.D., effective Friday, April 1, 2011. Dr. Kiral will complete his term on the Board of Directors, however, he will not seek reelection during the annual shareholder meeting held in September. To affect a smooth transition, Dr. Kiral and the company have entered into a two-year consulting agreement. More...
Oxygen Biotherapeutics Reports Financial Results for Third Quarter FY2011
MORRISVILLE, N.C., Mar 21, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) third quarter ended January 31, 2011. More...
Oxygen Biotherapeutics Announces Third Quarter FY2011 Financial Results Conference Call and Webcast
MORRISVILLE, N.C., Mar 14, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that the Company plans to report third quarter fiscal year 2011 financial results on Form 10-Q on Monday, March 21, 2011. Oxygen's Chairman and CEO Chris Stern and Chief Financial Officer Michael Jebsen will host a conference call and live webcast to discuss the results on Tuesday, March 22, 2011, at 11 a.m. EDT. More...
Oxygen Biotherapeutics Signs Agreement to Sell DERMACYTE Products to Mexican Sales and Distribution Company
MORRISVILLE, N.C., Mar 10, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has entered into an agreement with independently owned and operated Comercial Uni2, S.A. de C.V. of Mexico, for the sale of DERMACYTE products. Per the terms of the agreement, Comercial Uni2 has exclusive rights to sell and distribute Oxygen Biotherapeutics' DERMACYTE® skin care products throughout Mexico. More...
Oxygen Biotherapeutics Receives U.S. Army Grant for Studies of Oxycyte(R), a Novel Traumatic Brain Injury Therapeutic for Combat Casualties
MORRISVILLE, N.C., Mar 2, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has received a $2.075 million, two-year grant from the U.S. Army to study the Company's proprietary Oxycyte(R) PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury (TBI).
Perfluorocarbon (PFC) emulsions, as a therapeutic class, are known to interact with the reticuloendothelial system as part of the clearance mechanism, as well as affect the number of circulating platelets. The preclinical studies supported by this grant will examine the effects of Oxycyte on the immune system, platelet function and distribution, as well as the safety and efficacy of platelet transfusion, which can be necessary for patients with TBI and related polytrauma. Additionally studies will be conducted to further evaluate the pharmacokinetics of PFCs in relevant species to aid in data interpretation. These studies will help determine the safety profile of Oxycyte PFC emulsion.. More...
Oxygen Biotherapeutics and Hackensack University Medical Center Sign Research Contract Funded by the U.S. Department of Defense to Study Wound Healing Properties of Wundecyte(TM) Gel
DURHAM, N.C., Jan 28, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SWX:OXBT) today announced it has signed a research contract with Hackensack University Medical Center (HUMC) to research wound healing properties of the Oxygen Biotherapeutics' Wundecyte(TM) perfluorocarbon (PFC) and its novel oxygen-producing bandage for treatment of full-thickness excisional wounds and partial thickness burns. The preclinical study will also evaluate Wundecyte's ability to prevent scar formation and improve infection control. This project will be funded by the U.S. Department of Defense. More...
Oxygen Biotherapeutics Signs Agreement to Sell DERMACYTE Products to Swiss Sales and Distribution Company
DURHAM, N.C. and ZURICH, Switzerland, Jan 12, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT) today announced it has entered into an agreement with the newly formed, independently owned and operated DERMACYTE Switzerland Ltd. (DSL) of Zurich for the sale of DERMACYTE products. Per the terms of the agreement, DSL has exclusive rights to sell and distribute Oxygen Biotherapeutics' DERMACYTE(R) skin care products that it purchases throughout the European Union, Switzerland and Russia. The agreement also grants DSL the option to add South America as an exclusive territory if purchase volume milestones are achieved. More...
Oxygen Biotherapeutics and Sarasota Medical Products Sign Binding Letter of Intent to Pursue Joint Research and Development in Chronic Ischemic Wound Care
DURHAM, N.C., Dec 16, 2010 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) and privately held Sarasota Medical Products, Inc. (SMP) of Sarasota, FL, today announced they signed a Binding Letter of Intent to determine the feasibility of pursuing a joint research and development venture for treating chronic ischemic wounds. The venture will be based on combining Oxygen's Wundecyte(TM) PFC formulation with SMP's topical medical devices. More...
Oxygen Biotherapeutics Reports Second Quarter FY2011 Financial Results
DURHAM, N.C., Dec 9, 2010 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) second quarter ended October 31, 2010. More...
Oxygen Biotherapeutics Announces Date for Second Quarter FY2011 Financial Results Conference Call and Webcast
DURHAM, N.C., Dec. 3, 2010 /PRNewswire via COMTEX/ --
Oxygen Biotherapeutics, Inc. (Nasdaq: OXBT) (SIX Swiss Exchange: OXBT) today announced that the Company plans to report second quarter fiscal year 2011 financial results on Thursday, December 9, 2010. Oxygen's Chairman and CEO Chris Stern, and Chief Financial Officer Michael Jebsen, will host a conference call and live webcast to discuss the results on Friday, December 10, 2010 at 11 a.m. EST. More...
Oxygen Biotherapeutics Awarded $244,479 Grant Under the Patient Protection and Affordable Care Program
DURHAM, N.C., Nov 2, 2010 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has received nearly $245,000 in a grant under the Patient Protection and Affordable Care Program Act of 2010 (PPACA). The award was given for the Company's qualified investments under Section 48D of the PPACA for the clinical development of Oxycyte(R) perfluorocarbon emulsion for traumatic brain injury (TBI) and spinal cord injury. More...
DERMACYTE® Skin Care Products Secure Key Listing on DermStore.com, a Leading Dermatologic and Beauty E-tail Web Site
DURHAM, N.C., Oct 20, 2010 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced DERMACYTE(R) skin care products are now available for purchase on a leading on-line skin care site, www.DermStore.com. This popular beauty product outlet complements the Company's e-tail site, www.buydermacyte.com, broadening accessibility for consumers and increasing brand awareness. More...
DERMACYTE® Skin Care Products Secure Major Listing on BeautyRiche.com, a Leading Dermatologic and Beauty E-Tail Web Site
DURHAM, N.C., Oct 19, 2010 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced DERMACYTE(R) skin care products are now available for purchase on a leading beauty and dermatologic e-tail website www.BeautyRiche.com. This popular beauty product outlet complements Oxygen's e-tail site, www.buydermacyte.com, broadening accessibility for consumers and increasing brand awareness. More...
Oxygen Biotherapeutics Enters Into Purchase Agreement to Sell $5 Million of Unsecured Promissory Notes to Vatea Fund
DURHAM, N.C., Oct 13, 2010 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) entered into a Note Purchase Agreement with JP SPC 1 Vatea, Segregated Portfolio whereby the Company agreed to issue and sell to the Vatea Fund an aggregate of $5 million of senior unsecured promissory notes in a series of closings between October 31, 2010, and December 31, 2010. Vatea is a party to a securities purchase agreement with the Company, dated June 8, 2009, and subsequently amended. Vatea is the Company's largest shareholder, holding approximately 13.68% of the Company's outstanding common stock. In addition, Gregory Pepin, a director of the Company, is Investment Manager to the Vatea Fund. More...
Oxygen Biotherapeutics to Showcase New DERMACYTE® Oxygen-Enriched Lotions at Leading Spa and Resort Conference in New York City
DURHAM, N.C., Sep 27, 2010 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) will showcase for the first time its DERMACYTE oxygen-rich skin care products at the Spa & Resort/Medical Aesthetics Spa Conference and Expo at the Jacob K. Javits Convention Center in New York City starting tomorrow. The conference is open to the public from 10 AM to 5 PM on September 28-29, 2010. Free DERMACYTE Oxygen Concentrate samples will be available while supplies last at our Booth #5020. More...
Oxygen Biotherapeutics Receives DSMB Approval to Proceed to the Next Cohort in Its Phase II-B Clinical Trial for Traumatic Brain Injury
DURHAM, N.C., Sep 23, 2010 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte(R) emulsion in patients with severe non-penetrating traumatic brain injury. Due to the double-blind design of the study, specific results will not be reported to the company until the trial closes. More...
U.S. Navy Broadens CRADA With Oxygen Biotherapeutics to Include Preclinical Studies Assessing Oxycyte(R) for Spinal Cord Injury Due to Decompression Sickness and for Hemorrhagic Shock
DURHAM, N.C., Sep 20, 2010 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has amended an existing Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC) to include preclinical trials using swine models to assess the safety and efficacy of Oxygen Biotherapeutics' proprietary Oxycyte(R) perfluorocarbon emulsion (PFCE) for spinal cord injury (SCI) due to decompression sickness (DCS), and for hemorrhagic shock. More...
